Table 5. Subgroup analysis.
| Parameter | Median OS, 95% CI (months) | P value |
|---|---|---|
| Gender | 0.23 | |
| Male | 14.8 (9.8–19.8) | |
| Female | 10.6 (5.8–15.4) | |
| Age (years) | 0.33 | |
| <70 | 12.8 (8.6–16.9) | |
| ≥70 | 14.8 (8.6–21.06) | |
| Prior lines | 0.76 | |
| 1 line | NR | |
| ≥2 lines | 12.8 (8.9–16.7) | |
| Histology | 0.74 | |
| Squamous | 14.8 (7.1–22.5) | |
| Non-squamous | 11.7 (8.4–15.1) | |
| NOS | NR | |
| Smoking status | 0.43 | |
| Smoker | 12.8 (9.8–15.8) | |
| Former | 12.8 (7.2–18.4) | |
| Non-smoker | 10.5 (0.0001–21.4) | |
| CNS mts | 0.0001 | |
| Yes | 14.8 (11.5–17.3) | |
| No | 5.09 (0.3–9.8) | |
| PS | 0.006 | |
| 0 | NR | |
| 1 | 11.79 (8.5–15) | |
| 2 | 3.4 (2.3–4.4) | |
| Mutation | 0.12 | |
| EGFR/ALK | 4.8 (2.1–7.5) | |
| Wild type | 12.8 (9.6–16.05) |
OS, overall survival; NR, not reached; NOS, not otherwise specified; CNS, central nervous system; PS, performance status; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase.